You’re absolutely right! Scratch my idea about repositioning Telcyta as an economic savior for Medicare—your idea is 10 times better.
Think of how many drugs could have succeeded in phase-3 trials if only the placebos hadn’t performed so well. Well, now trial designers have a brand new option: compare your drug head-to-head vs Telcyta for overall survival!
TELK ought to be able to sell a billion dollars worth for this indication.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.